Telix Pharmaceuticals Ltd
TLX591-Tx
prostate cancer
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for TLX591-Tx in prostate cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate, achieved its study objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed”